RecruitingEarly Phase 1NCT05432518

Pilot Trial for Treatment of Recurrent Glioblastoma

Biomarker and Tumor Cell Culture-Driven Pilot Trial for Treatment of Recurrent Glioblastoma


Sponsor

AHS Cancer Control Alberta

Enrollment

10 participants

Start Date

Jun 27, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their recurrent GBM tumor resected at the time of surgery. It will be aimed to gather preliminary information on the study intervention and the feasibility of conducting a full-scale trial.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new treatment approach for people with glioblastoma (an aggressive brain tumor) that has come back after initial treatment. The trial uses a combination of therapies delivered at the time of repeat surgery, aiming to slow the cancer's return. **You may be eligible if:** - You are 18 or older - You have a confirmed glioblastoma (IDH-wild type) that has come back for the first or second time after radiation and chemotherapy - Your tumor can be surgically removed - You are in reasonably good physical health (able to carry out daily activities) - Women who could become pregnant must have a negative pregnancy test **You may NOT be eligible if:** - Your tumor cannot be safely removed with surgery - You are not healthy enough for surgery - You have other conditions that exclude study participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAfatinib

Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.

DRUGDasatinib

Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.

DRUGPalbociclib

Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.

DRUGEverolimus

Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.

DRUGOlaparib

Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.


Locations(1)

Arthur J.E. Child Comprehensive Cancer Centre

Calgary, Alberta, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05432518


Related Trials